Nuvation Bio Inc (NUVB) - Total Liabilities
Based on the latest financial reports, Nuvation Bio Inc (NUVB) has total liabilities worth $290.68 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nuvation Bio Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Nuvation Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See NUVB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Nuvation Bio Inc Competitors by Total Liabilities
The table below lists competitors of Nuvation Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atrium Ljungberg AB (publ)
ST:ATRLJ-B
|
Sweden | Skr36.67 Billion |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
China | CN¥1.75 Billion |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
USA | $815.06 Million |
|
Coty Inc
NYSE:COTY
|
USA | $6.87 Billion |
|
Grupo Gigante S. A. B. de C. V
MX:GIGANTE
|
Mexico | MX$26.66 Billion |
|
Faraday Technology Corp
TW:3035
|
Taiwan | NT$5.40 Billion |
|
SÜSS MicroTec SE
F:SMHN
|
Germany | €218.69 Million |
|
Montana Aerospace AG
SW:AERO
|
Switzerland | CHF672.59 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Nuvation Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nuvation Bio Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvation Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvation Bio Inc (2018–2025)
The table below shows the annual total liabilities of Nuvation Bio Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $289.11 Million | +276.25% |
| 2024-12-31 | $76.84 Million | +369.61% |
| 2023-12-31 | $16.36 Million | -4.12% |
| 2022-12-31 | $17.07 Million | -43.41% |
| 2021-12-31 | $30.15 Million | +349.52% |
| 2020-12-31 | $6.71 Million | +109.36% |
| 2019-12-31 | $3.20 Million | +255.21% |
| 2018-12-31 | $902.00K | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more